Objectives

After participating in this educational activity, attendees should be able to:

1|Discuss the pharmacology and importance of SGLT1&2 inhibitors 
2|List guideline recommended treatment for T2DM and HF
3|Analyze literature surrounding sotagliflozin
4|Evaluate the role of sotagliflozin in T2DM, HF, and CKD.
 

 Faculty

Ashley Iacoviello, PharmD
PGY2 HSPAL Residents
Department of Pharmacy Services
Baystate Medical Center, Springfield, MA
Faculty Disclosure

The design and content of Baystate Continuing Interprofessional Education (CE) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options. Any relevant financial relationships are mitigated prior to the educational activity.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Accreditation Statement
In support of improving patient care, Baystate Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Pharmacists
Baystate Health designates this activity for a maximum of 1.0 contact hours (s) for pharmacists. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. 

Session date: 
08/14/2023 - 2:00pm to 3:00pm EDT
Location: 
Webinar
Baystate Medical Center
759 Chestnut St
Springfield, MA 01199
United States
  • 1.00 ACPE Contact Hours

Please login or register to take this course.